- AbbVie Inc. showcases strong revenue growth, defying challenges from Humira's patent expiration.
- Analysts project significant upside potential with an average target price of $214.64.
- Current brokerage consensus rates AbbVie as "Outperform," reflecting positive market sentiment.
AbbVie Inc. (ABBV, Financial) has proven its resilience by achieving robust growth, even as it faces the patent expiration of its blockbuster drug, Humira. By strategically expanding its product portfolio, AbbVie has maintained a solid financial trajectory. In the fiscal fourth quarter of 2025, AbbVie announced a commendable 5.6% increase in revenue, totaling $15.1 billion, and exceeding market expectations. A substantial portion of this growth can be attributed to the remarkable performance of Rinvoq and Skyrizi, with their combined sales surging by 51% in 2024.
Wall Street Analysts Forecast
The one-year price targets from 24 financial analysts imply a bullish outlook for AbbVie Inc (ABBV, Financial). The average target price is set at $214.64, with estimations ranging from a high of $251.00 to a low of $173.00. This average target suggests an impressive upside potential of 24.08% from its current trading price of $172.99. For more in-depth estimates, investors can visit the AbbVie Inc (ABBV) Forecast page.
The consensus recommendation from 27 brokerage firms positions AbbVie Inc (ABBV, Financial) at an average brokerage recommendation of 2.0, categorizing it as an "Outperform" investment. This recommendation scale varies from 1, indicating a Strong Buy, to 5, signaling a Sell, placing AbbVie comfortably in a favorable investment position.
According to GuruFocus metrics, the estimated GF Value for AbbVie Inc (ABBV, Financial) over the next year is projected at $168.00. This value suggests a potential downside of 2.88% relative to the current market price of $172.99. The GF Value is GuruFocus' computation of the stock's fair trading value, derived from historical trading multiples, prior business growth, and future business performance forecasts. Investors can access further data on the AbbVie Inc (ABBV) Summary page.
Also check out: (Free Trial)
